New drug combo targets tough lung cancer mutation

NCT ID NCT06816992

Recruiting now Disease control Sponsor: ORIC Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tumors. About 76 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ORIC-114 (oral drug) plus amivantamab (injectable drug)
What this could lead to: If this combination works, it could offer a new treatment option for people with a hard-to-treat form of lung cancer that has specific genetic changes.
What could go wrong: This is an early Phase 1b trial with only 76 participants, so the main goal is safety and dosing, not proof of effectiveness. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR EXON 20 INSERTION MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR EXON 20 INSERTION MUTATIONS EGFR-MUTATED NSCLC NSCLC SOLID TUMORS

Contacts and locations

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Peter MacCallum Cancer Centre
NOT_YET_RECRUITING

Melbourne, Victoria, 03000, Australia
The Princess Margaret Hospital
NOT_YET_RECRUITING

Toronto, Ontario, M5G 1Z5, Canada
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.